Analysis

Xarelto User Faces Hard Sell In 1st Philly Mass Tort Trial

By Matt Fair (November 3, 2017, 6:43 PM EDT) -- As the first Philadelphia trial over alleged injuries from the blood-thinner Xarelto prepares to open on Monday, attorneys say defense verdicts notched by Johnson & Johnson and Bayer AG in three bellwether federal cases over the drug earlier this year show the challenge for plaintiffs in proving their claims.

The companies have managed to convince federal juries in Louisiana and Mississippi to clear them from claims that the drug, which is used to reduce the risk of stroke and life-threatening blood clots in patients with a certain heart rhythm disorder, caused internal bleeding.

James Heller, chair of Cozen O'Connor's products liability...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!